Steven Pieper files SEC Form 4 disclosures for XERIS PHARMACEUTICALS INC. They have made 2 open-market trades across 1 company since 2021, most recently 2026-10-01.
CIK 0001875714
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $105K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XERS | 1,351,053 | $14.0M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XERS | SELL · 10b5-1 | 2026-10-01 | 2026-10-02 | $9.41 | $47K | +7.1% | — | — |
| XERS | SELL · 10b5-1 | 2026-09-01 | 2026-09-01 | $8.50 | $43K | -11.6% | +7.9% | — |
| XERS | SELL · 10b5-1 | 2026-08-12 | 2026-08-12 | $8.50 | $43K | +0.5% | -14.2% | — |
| XERS | SELL · 10b5-1 | 2026-07-06 | 2026-07-07 | $8.52 | $383K | -0.3% | -16.6% | +14.9% |
| XERS | BUY | 2023-11-20 | 2023-11-21 | $1.95 | $55K | +3.3% | +14.8% | +72.7% |
| XERS | BUY | 2021-11-10 | 2021-11-12 | $2.00 | $50K | -7.2% | -6.8% | +5.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.